Cell based metabolic barriers to glucose diffusion: Macrophages and continuous glucose monitoring

被引:31
作者
Klueh, Ulrike [1 ,2 ]
Frailey, Jackman T. [1 ,2 ]
Qiao, Yi [1 ,2 ]
Antar, Omar [1 ,2 ]
Kreutzera, Donald L. [1 ,2 ]
机构
[1] Univ Connecticut, Sch Med, Ctr Mol Tissue Engn, Farmington, CT 06030 USA
[2] Univ Connecticut, Sch Med, Dept Surg, Farmington, CT 06030 USA
关键词
Macrophages; Diabetes; Implantable glucose sensor; Continuous glucose monitoring; Glucose metabolism; PERFORMANCE; THERAPY; SENSORS;
D O I
10.1016/j.biomaterials.2014.01.001
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
It is assumed that MQ are central to glucose sensor bio-fouling and therefore have a major negative impact on continuous glucose monitoring (CGM) performance in vivo. However to our knowledge there is no data in the literature to directly support or refute this assumption. Since glucose and oxygen (O-2) are key to glucose sensor function in vivo, understanding and controlling glucose and O-2 metabolic activity of MQ is likely key to successful glucose sensor performance. We hypothesized that the accumulation of MQ at the glucose sensor-tissue interface will act as "Cell Based Metabolic Barriers" (CBMB) to glucose diffusing from the interstitial tissue compartment to the implanted glucose sensor and as such creating an artificially low sensor output, thereby compromising sensor function and CGM. Our studies demonstrated that 1) direct injections of MQ at in vivo sensor implantation sites dramatically decreased sensor output (measured in nA), 2) addition of MQ to glucose sensors in vitro resulted in a rapid and dramatic fall in sensor output and 3) lymphocytes did not affect sensor function in vitro or in vivo. These data support our hypothesis that MQ can act as metabolic barriers to glucose and O-2 diffusion in vivo and in vitro. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3145 / 3153
页数:9
相关论文
共 22 条
[1]   Foreign body reaction to biomaterials [J].
Anderson, James M. ;
Rodriguez, Analiz ;
Chang, David T. .
SEMINARS IN IMMUNOLOGY, 2008, 20 (02) :86-100
[2]   Early and Intensive Therapy for Management of Hyperglycemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes [J].
Dailey, George .
CLINICAL THERAPEUTICS, 2011, 33 (06) :665-678
[3]   Remote Glucose Monitoring in Camp Setting Reduces the Risk of Prolonged Nocturnal Hypoglycemia [J].
DeSalvo, Daniel J. ;
Keith-Hynes, Patrick ;
Peyser, Thomas ;
Place, Jerome ;
Caswell, Kim ;
Wilson, Darrell M. ;
Harris, Breanne ;
Clinton, Paula ;
Kovatchev, Boris ;
Buckingham, Bruce A. .
DIABETES TECHNOLOGY & THERAPEUTICS, 2014, 16 (01) :1-7
[4]  
Feldman Ben, 2003, Diabetes Technol Ther, V5, P769, DOI 10.1089/152091503322526978
[5]   Performance of subcutaneously implanted glucose sensors for continuous monitoring [J].
Gerritsen, M ;
Jansen, JA ;
Lutterman, JA .
NETHERLANDS JOURNAL OF MEDICINE, 1999, 54 (04) :167-179
[6]  
Gerritsen M, 2001, J BIOMED MATER RES, V54, P69, DOI 10.1002/1097-4636(200101)54:1<69::AID-JBM8>3.3.CO
[7]  
2-H
[8]  
Hoss U, DIABETES TECHNOL THE, V12, P591
[9]  
Klonoff David C, 2007, J Diabetes Sci Technol, V1, P797
[10]   Continuous glucose monitoring - Roadmap for 21st century diabetes therapy [J].
Klonoff, DC .
DIABETES CARE, 2005, 28 (05) :1231-1239